Tag: Rexin-G
REXIN-G, a Tumor-Targeted Genetic Medicine for Metastatic Cancer, Gains Phase 3 Product Designation from the U.S. FDA
SAN MARINO, Calif. /eNewsChannels/ -- Epeius Bio announced today that the U.S. FDA has granted Phase 3 status for Company's lead anti-cancer agent, Rexin-G, the first, and so far only, targeted gene delivery system developed to seek-out and destroy metastatic cancer.
Epeius Bio's Rexin-G® Receives High-tech Validation as Strategic Anti-cancer Agent
SAN MARINO, Calif. -- Epeius Biotechnologies Corporation, an emerging leader in the field of targeted genetic medicine, gained international validation of the cutting-edge science...
Epeius Biotech Reports Dose-Dependent Efficacy and Survival Benefits, Efficacy of Rexin-G in Metastatic Pancreas Cancer
SAN MARINO, Calif. -- Epeius Biotechnologies (www.epeiusbiotech.com) confirms the first real breakthrough for pancreatic cancer seen in years; publishes a landmark report of tumor-targeted...
Tumor-targeted REXIN-G Quells Metastatic Osteosarcoma, Prostate Cancer, and Pancreas Cancer as Stand-alone Therapy
SAN MARINO, Calif. -- Epeius Biotechnologies Corporation today announced more stunning results of its pioneering clinical studies of Rexin-G, the world's first and, so...
Epeius Rexin-G Receives FDA Fast Track Designation for the Treatment of Pancreatic Cancer
SAN MARINO, Calif. -- Epeius Biotechnologies (www.epeiusbiotech.com) announced today that its lead product, Rexin-G, has been granted Fast Track designation by the U.S. Food...
The World's Smallest Hero! Epeius Bio's Rexin-G, Targeted Therapy for Metastatic Cancers
SAN MARINO, Calif. -- Epeius Biotechnologies' Rexin-G® is the world's smallest hero (epeiusbiotech.com). Imagine if you will, a tiny particle that can travel freely...
Epeius' Rexin-G Controls Tumor Growth and Improves Survival in Chemotherapy-Resistant Sarcoma and Osteosarcoma
SAN MARINO, Calif. -- Epeius Biotechnologies (www.epeiusbiotech.com) today announced the results of two related studies using Rexin-G, a tumor-targeted anti-cancer agent designed to seek-out...
Epeius Biotechnologies' Tumor-Targeted Rexin-G Receives FDA Orphan Drug Designation for The Treatment of Osteosarcoma
SAN MARINO, Calif. -- Epeius Biotechnologies Corporation today announced that Rexin-G has been granted Orphan Drug Designation by the U.S. Food and Drug Administration...
